<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00435656</url>
  </required_header>
  <id_info>
    <org_study_id>2006/11OCT/AC/189</org_study_id>
    <nct_id>NCT00435656</nct_id>
  </id_info>
  <brief_title>Pharmacogenetics of Antiretroviral Drugs</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <brief_summary>
    <textblock>
      In this research project, we will study the genetic determinants that influence the&#xD;
      pharmacokinetics of antiretroviral drugs used in the treatment of diseases caused by the HIV.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The development of new active substances is a continuous source of progress in&#xD;
      pharmacotherapy. However, the search for an optimal use of existing molecules constitutes&#xD;
      another possible way of progress. In the particular field of anti-infectious therapy, an&#xD;
      optimization of treatments could minimize the emergence of resistance phenomena that require&#xD;
      the continuous development of new active molecules.&#xD;
&#xD;
      Pharmacogenetics is the scientific discipline seeking to improve the response to drug&#xD;
      therapies (better clinical efficiency and reduction of side effects) by taking into&#xD;
      consideration the genetic characteristics of the patient. Drugs with a narrow therapeutic&#xD;
      index constitute a main target of this emerging field. The combination of therapeutic drug&#xD;
      monitoring and pharmacogenetics already allows to optimize the use of some drugs among which&#xD;
      oral anticoagulants, immunosuppressants, antiepileptics, antidepressors, antibiotics or&#xD;
      antivirals….&#xD;
&#xD;
      In this research project, we will study the genetic determinants that influence the&#xD;
      pharmacokinetics of antiretroviral drugs used in the treatment of diseases caused by the HIV.&#xD;
      We will put a particular emphasis on viral protease inhibitors (atazanavir, saquinavir,&#xD;
      lopinavir, ritonavir)and non-nucleosides reverse transcriptase inhibitors (nevirapine and&#xD;
      efavirenz). For those drugs, the clinician often faces a double therapeutic risk, either of&#xD;
      insufficient dosing (clinical inefficacy and emergence of resistance) or of excessive dosing&#xD;
      (toxicity). The optimization of drug dosing is especially crucial because some of these drugs&#xD;
      often represent the last choice in multi-resistant patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <enrollment type="Anticipated">200</enrollment>
  <condition>HIV Infections</condition>
  <eligibility>
    <study_pop>
      <textblock>
        HIV infected patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV infected patients&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vincent Haufroid, PharmD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques universitaires saint Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <study_first_submitted>February 14, 2007</study_first_submitted>
  <study_first_submitted_qc>February 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 15, 2007</study_first_posted>
  <last_update_submitted>August 24, 2011</last_update_submitted>
  <last_update_submitted_qc>August 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 25, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</investigator_affiliation>
    <investigator_full_name>Laure Elens</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Human immunodeficiency virus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

